secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0001558370-25-009989
Event type: litigation
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix BioTherapeutics resolves stockholder class action; pays $160k fees
---------------------------------------------------------------------------

- Plaintiff Kevin Mathew Thomas filed suit on March 10, 2025, challenging certain bylaws provisions under Delaware law.
- On May 8, 2025, the Board amended the challenged bylaws, rendering plaintiff's claims moot.
- Company agreed to pay $160,000 in fees and expenses to plaintiff's counsel; no admission of wrongdoing.
- Court entered dismissal with prejudice as to plaintiff on July 23, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025009989/0001558370-25-009989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025009989/plx-20250801x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-009989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer